Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 11/20 | 0.47 |
| ▸ | PPARD | Q03181 | 7/20 | 0.47 |
| ▸ | PPARG | P37231 | 6/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | TERT | O14746 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | ALOX15B | O15296 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16079412 | 0.87 | FFAR1 (0.45) | FFAR1PPARDPPARGCYP19A1TERT | |
| SCHEMBL30295621 | 0.86 | HTR1A (0.43) | FFAR1PPARDPPARGCYP19A1CA2 | |
| SCHEMBL6100632 | 0.86 | HTR1A (0.43) | FFAR1PPARDPPARGCYP19A1CA2 | |
| SCHEMBL15292428 | 0.81 | FFAR1 (0.69) | FFAR1PPARDPPARG | |
| SCHEMBL15299338 | 0.81 | FFAR1 (0.69) | FFAR1PPARDPPARG | |
| SCHEMBL28705121 | 0.80 | HCRTR2 (0.40) | FFAR1PPARDPPARGCYP19A1CA2 | |
| SCHEMBL6100820 | 0.79 | PPARD (0.40) | FFAR1PPARDPPARGCA2 | |
| SCHEMBL4704202 | 0.79 | MAP3K14 (0.50) | FFAR1PPARDPPARGCA2 | |
| SCHEMBL17361476 | 0.79 | FFAR1 (0.45) | FFAR1PPARDPPARGCA2 | |
| SCHEMBL2317460 | 0.79 | CYP3A4 (0.51) | FFAR1PPARDPPARGALOX15ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190280-A1 | Thiazole And Oxazole Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2011-08-04 | — | — | US | disclosed |
| US-20110190280-A1 | Thiazole And Oxazole Kinase Inhibitors | GLAXOSMITHKLINE LLC | 2011-08-04 | — | — | US | disclosed |
| WO-2009032667-A1 | THIAZOLE AND OXAZOLE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190280-A1 | Thiazole And Oxazole Kinase Inhibitors | PDXK, MAP3K1, MAP4K2 | FFAR1 3273/4885PPARD 902/4885PPARG 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.